drugset / Trial / NCT01241539
Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis
Non-randomizedSingle-groupOpen-label
Summary
The current study will allow the assessment of pharmacokinetics, pharmacodynamics, elimination rate and clearance of dabigatran etexilate during and following haemodialysis in ESRD patients.
Timeline
- Start
- 2010-11
- Primary completion
- 2011-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabigatran etexilate | Unknown | 75 mg | Oral |
| Subject | Dabigatran etexilate | Unknown | 110 mg | Oral |
| Subject | Dabigatran etexilate | Unknown | 150 mg | Oral |